Evoke Pharma, Inc. (EVOK)

NASDAQ: EVOK · Real-Time Price · USD
5.40
-0.14 (-2.53%)
Oct 22, 2024, 4:00 PM EDT - Market closed
-2.53%
Market Cap 4.42M
Revenue (ttm) 7.53M
Net Income (ttm) -6.53M
Shares Out 819.27K
EPS (ttm) -8.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 14,449
Open 5.55
Previous Close 5.54
Day's Range 5.40 - 5.57
52-Week Range 3.54 - 17.88
Beta 0.38
Analysts n/a
Price Target n/a
Earnings Date Nov 7, 2024

About EVOK

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beac... [Read more]

Sector Healthcare
IPO Date Sep 25, 2013
Employees 4
Stock Exchange NASDAQ
Ticker Symbol EVOK
Full Company Profile

Financial Performance

In 2023, Evoke Pharma's revenue was $5.18 million, an increase of 106.51% compared to the previous year's $2.51 million. Losses were -$7.79 million, -5.25% less than in 2022.

Financial Statements

News

Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors

SOLANA BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an...

22 hours ago - GlobeNewsWire

Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion

Nantahala to nominate 2 board seats Portion of the proceeds received from warrants executed at $8.16/share SOLANA BEACH, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a ...

21 days ago - GlobeNewsWire

Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments

Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesis Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesis

4 weeks ago - GlobeNewsWire

XLR8 America and EVoke Systems Partner to Deliver Smarter EV Charging Stations to the Parking Industry

SAN DIEGO--(BUSINESS WIRE)-- #CleanTech--EVoke Partnership.

4 weeks ago - Business Wire

Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference

SOLANA BEACH, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with a...

6 weeks ago - GlobeNewsWire

Evoke Pharma to Present at H.C. Wainwright's 26th Annual Global Investment Conference

SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with a...

6 weeks ago - GlobeNewsWire

Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results

GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10 million

2 months ago - GlobeNewsWire

Evoke Pharma, Inc. Supports Gastroparesis Awareness Month

Collaborating with advocacy groups to amplify gastroparesis awareness for millions of patients worldwide Call for action to improve health and access for patients SOLANA BEACH, Calif., Aug. 08, 2024 (...

2 months ago - GlobeNewsWire

Evoke Pharma, Inc. Announces Reverse Stock Split

SOLANA BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK) , a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with a...

3 months ago - GlobeNewsWire

Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI

Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024 Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer SOLANA BEACH, Cali...

4 months ago - GlobeNewsWire

Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference

SOLANA BEACH, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.  (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an...

5 months ago - GlobeNewsWire

Evoke Pharma Reports First Quarter 2024 Financial Results

114% year-over-year increase in net product sales 70% prescriber growth in Q1 2024 compared to Q4 2023 Growing sales metrics reaffirms company's $14M net revenue guidance for 2024

5 months ago - GlobeNewsWire

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications

Michael Cline, DO., Medical Director Gastroparesis Clinic, Cleveland Clinic to present Michael Cline, DO., Medical Director Gastroparesis Clinic, Cleveland Clinic to present

6 months ago - GlobeNewsWire

Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer

SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with a...

7 months ago - GlobeNewsWire

Evoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call Transcript

Evoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call Transcript

7 months ago - Seeking Alpha

Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results

Fiscal year 2023 net product sales from prescriptions totaled approximately $5.2M, a 107% increase from 2022

7 months ago - GlobeNewsWire

Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024

SOLANA BEACH, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis...

8 months ago - GlobeNewsWire

Evoke Pharma Announces Closing of $7.5 Million Public Offering

Potential for Additional $22.5 Million in the Event of Exercise of Common Warrants in Full Potential for Additional $22.5 Million in the Event of Exercise of Common Warrants in Full

8 months ago - GlobeNewsWire

Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million

SOLANA BEACH, Calif., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an...

9 months ago - GlobeNewsWire

Kestra Private Wealth Services Announces New Partnership Between Maven Bridge Capital and Evoke Wealth Management

AUSTIN, Texas--(BUSINESS WIRE)--Kestra Private Wealth Services Announces New Partnership Between Maven Bridge Capital and Evoke Wealth Management.

9 months ago - Business Wire

Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent

SOLANA BEACH, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an...

11 months ago - GlobeNewsWire

United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI

SOLANA BEACH, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an...

1 year ago - GlobeNewsWire

Evoke Pharma Reports Third Quarter 2023 Financial Results

38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year Seventh Straight Prescription Fill Increase Since Q1 2022 21% Increase Compared to Q2 2023; 95% Increase Year-Over-Year “Superiori...

1 year ago - GlobeNewsWire

Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023

Reduction in emergency department visits, hospitalizations and office visits caused diabetic gastroparesis patients and insurers to save over $15,000 for each patient in a six-month period by treating...

1 year ago - GlobeNewsWire

Evoke Pharma's Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 An

SOLANA BEACH, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an...

1 year ago - GlobeNewsWire